Ambrose Healthcare Ltd (Ambrose Healthcare), a specialist pharmaceutical company established to develop and provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting, announces today that it has appointed Toby Wilson Waterworth as Chair of the Board.
Toby is a commercially focused Board member, senior executive, and healthcare entrepreneur with a 30+ year track record of leading and developing high growth medical technology companies to deliver patient benefits and investor returns.
Having worked in the healthcare industry across North America, UK, Europe, and the Middle/Far East, he has acquired a deep knowledge of technology innovation and commercialisation, the hospital, specialist care, healthcare and pharmaceutical environments, and capital markets.
Toby has led teams responsible for raising over $200m in both public markets and in private equity/grant transactions and building companies delivering shareholder value approaching $1BN. Toby has established international industry networks built through positions in both quoted and unquoted groups and as an international Dealmaker and adviser in healthcare to the British Government.
Toby is a Fellow of the Institute of Chartered Accountants England and Wales, a Fellow of the Royal Society of Medicine and has a BSc in Business Economics, University of Hull, UK.
Toby joins Ambrose Healthcare, to support the Company as it spearheads international collaborations for developing and providing access to new therapies for treating rare and other hospital managed diseases.
The U.S. NIH recognises some 7,000 rare diseases[1], affecting around 400 million people globally[2], for which approximately 600 therapies have been approved to date by the U.S. Food and Drug Administration{3]. As such there is still much to be done to close this gap.
Toby Wilson Waterworth, Chair of the Board, Ambrose Healthcare commented:
“I am delighted to be appointed Chair and to be leading this exciting young specialist pharmaceutical company. It is spearheading a patient-focused approach that is drawing together the necessary skills, experience, and organisations in our international networks for the benefit of rare disease and hospital-managed patient groups.
In my experience, this market-pull and collaborative approach has the potential to overcome many challenges historically experienced in the development of new treatments for these patients.”
About Ambrose Healthcare (www.ambrosehc.com)
Ambrose Healthcare Ltd is a specialist pharmaceutical company, with ambitious plans to address ‘market pull’ – the call from patient groups and the medical community – to provide treatments for rare diseases and the unmet medical needs of patients managed in a hospital or specialist care setting.
Whilst the NIH lists more than 7,000 rare diseases[1], FDA reports only 600 drug approvals to date in 2020[3]. Some 400 million people worldwide are affected by rare diseases[2].
The Ambrose Healthcare team is seeking to replicate the success of its previous venture, where, applying the same rare disease, hospital focused strategy, and receiving $50M of investment in equity and grants, it delivered a product portfolio independently valued at $500M (Top 4 Global Accountancy Firm).
Ambrose Healthcare, through acquisition, licencing and collaboration, is developing a portfolio of commercial and clinical stage therapeutic assets.
The company will commercialise its products in its core markets of the US, Europe, and the Middle East, and in other territories via licencing or distribution agreements with established pharmaceutical companies.
References:
1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)
2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)
3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/
Forward looking statements
While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.
For more information, please contact:
Adam Michael, Director of Communications
adam.michael@ambrosehc.com +44 7775 881 813